Story perspectives

Novartis and SciNeuro Join Forces for $1.7B Alzheimer's Deal

1/13/2026

Summary

Story summary

On January 12, 2026, Novartis AG and SciNeuro Pharmaceuticals signed a licensing deal valued at nearly $1.7 billion to develop Alzheimer's antibody treatments that address about 55 million people globally.
SciNeuro will receive an upfront payment of $165 million.
The agreement could authorize up to $1.5 billion in milestones and royalties.
The partnership aims to improve brain drug delivery and reflects a shift toward complex pathways beyond amyloid beta.

History

Historical Context

The U.S. government enacted the National Alzheimer's Project Act in 2011, allocating $50 million to the National Institutes of Health for Alzheimer's research amid rising cases, which reached 5.4 million Americans. This initiative aimed to enhance treatment and prevention efforts, reflecting a broader commitment to combat Alzheimer's, now affecting 55 million globally, as seen in recent partnerships like the $1.7 billion deal between Novartis AG and SciNeuro Pharmaceuticals.

1 of 2

Story summary

On January 12, 2026, Novartis AG and SciNeuro Pharmaceuticals signed a licensing deal valued at nearly $1.7 billion to develop Alzheimer's antibody treatments that address about 55 million people globally.
SciNeuro will receive an upfront payment of $165 million.
The agreement could authorize up to $1.5 billion in milestones and royalties.
The partnership aims to improve brain drug delivery and reflects a shift toward complex pathways beyond amyloid beta.

1 / 2